Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infections

FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)0 sitesMarch 20, 2018

Overview

Phase: N/A
Intervention: Not specified
Conditions: Not specified
Sponsor: FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
Status: Not Yet Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 20, 2018

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)

Eligibility Criteria

Inclusion Criteria

•novel or re\-emerging influenza infections who take favipiravir (Avigan tablets) and any gender welcome.

Exclusion Criteria

•Pregnant women or women suspected of being pregnant
•Patients with known hypersensitivity to favipiravir or any of its excipients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown

N/A

Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid Arthritis

JPRN-jRCT1080222730Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)2,000

Unknown

N/A

Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid Arthritis

JPRN-jRCT1080222005Eisai Co., Ltd.2,000

Completed

N/A

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

JPRN-jRCT1080224672Eisai Co., Ltd.500

Completed

N/A

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

JPRN-jRCT1080224671Eisai Co., Ltd.3,750

Withdrawn

N/A

Clinical investigation of the safety and efficacy of ALIMAXX-B biliary stent for bile duct obstructioCBD obstructionmalignant biliary obstruction10018008

NL-OMON31943Alveolus, Inc.10